Hypoxia-inducible factors bronchopulmonary dysplasia-BPD

缺氧诱导因素支气管肺发育不良

基本信息

  • 批准号:
    7114953
  • 负责人:
  • 金额:
    $ 23.81万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1995
  • 资助国家:
    美国
  • 起止时间:
    1995-09-30 至 2009-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Diminished alveolar complexity and vascular development of the lung is a constant feature of bronchopulmonary dysplasia (BPD). It persists even now that oxygen therapy is used at much lower levels than 1-2 decades ago. The lung develops at low, fetal oxygen concentrations (3-5%), and, in vitro, it develops much better at these levels than in 21%. Endothelial and vascular growth is impaired at these higher oxygen levels. Epithelial and alveolar development, in turn, depend on critical interactions with the developing vasculature. Thus, the distal airways of fetal lung in 21% show much less branching. Angiogenesis is proceeding rapidly in the third trimester of gestation. Hypoxia-inducible factors HIF- 1 and -2 (HIFs) regulate critical growth factors, receptors, kinases, and other proteins in angiogenesis. Oxygen tension is the primary regulator of HIF- 1alpha and -2alpha, the key components of these transcription factors. Knocking down HIF-2 in lung throughout gestation, or in distal lung epithelium during the third trimester, results in oversimplified lung development and respiratory distress in newborn mice. Recently HIF prolyl-4- hydroxylases (P4Hs or PHDs) were found to catalyze O2-dependent degradation of HIFs. Inhibiting P4Hs with oxoglutarate analogs or iron chelators stabilize HIFs, increase VEGF, and cause angiogenesis. HIFspecific P4H inhibitors are being rapidly developed. In trials in cardiovascular medicine, angiogenic therapy with single growth factors has caused formation of dysmorphic or leaky vessels. "Flipping the switch" of HIFs in the normoxic lung can cause more balanced angiogenesis. We hypothesize that loss of HIFs promotes lung hypoplasia in BPD, and that stabilizing HIFs will promote more normal lung development in the premature neonate with evolving BPD. This proposal is for translational research to test the effect of new HIF-specific P4H inhibitors on lung in vitro and in vivo using the primate model of BPD. In vitro, P4H inhibition causes HIF-1alpha stability, VEGF expression, angiogenesis, and increased activity of kinases important in vascular growth. In lung explants, new HIF P4H inhibitors will be tested for their ability to stabilize HIFs and increase HIF-related proteins and kinase activities. In addition, HIF P4H inhibitor will be administered intravenously, intratracheally, and by both routes combined. Gas exchange, pulmonary mechanics and function, various clinical parameters, and HIF P4H inhibitor levels will be measured in vivo, and alveolar and vascular development, lung HIF proteins and HIF-related proteins and kinase activities, and tissue HIF P4H inhibitor levels will be quantitated ex vivo. Therapy at the level of HIF transcription factors to improve angiogenesis and alveolar development offers promise to prevent BPD.
描述(由申请人提供):

项目成果

期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Commentary on "Hypoxia, hypoxic signaling, tissue damage, and detection of reactive oxygen species (ROS)".
对“缺氧、缺氧信号传导、组织损伤和活性氧 (ROS) 检测”的评论。
  • DOI:
    10.1016/j.freeradbiomed.2005.12.008
  • 发表时间:
    2006
  • 期刊:
  • 影响因子:
    7.4
  • 作者:
    White,CarlW
  • 通讯作者:
    White,CarlW
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Carl W White其他文献

CXCL17 induces activation of human mast cells via MRGPRX2
CXCL17 通过 MRGPRX2 诱导人类肥大细胞激活
3 ROS : reactive oxygen species RT-qPCR : reverse transcription quantitative PCR SM : sulfur mustard SpO 2 : peripheral oxygen saturation tPA : tissue plasminogen activator
3 ROS : 活性氧 RT-qPCR : 逆转录定量 PCR SM : 硫芥 SpO 2 : 外周血氧饱和度 tPA : 组织纤溶酶原激活剂
  • DOI:
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Heidi J. Nick;Carly A Johnson;Amber R. Stewart;Sarah Christeson;A. Leslie;Bloomquist;Amanda S. Appel;A. Donkor;L. Veress;B. Logue;E. Preston;Bratcher;Carl W White
  • 通讯作者:
    Carl W White

Carl W White的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Carl W White', 18)}}的其他基金

Effect of vaping on COVID-19 infection
电子烟对 COVID-19 感染的影响
  • 批准号:
    10176655
  • 财政年份:
    2016
  • 资助金额:
    $ 23.81万
  • 项目类别:
Development of antidotes for toxic gases
有毒气体解毒剂的开发
  • 批准号:
    9145045
  • 财政年份:
    2016
  • 资助金额:
    $ 23.81万
  • 项目类别:
Development of antidotes for toxic gases
有毒气体解毒剂的开发
  • 批准号:
    9564911
  • 财政年份:
    2016
  • 资助金额:
    $ 23.81万
  • 项目类别:
New Developments in Chemical Countermeasures: CounterACT 2018
化学对抗新进展:CounterACT 2018
  • 批准号:
    9490163
  • 财政年份:
    2016
  • 资助金额:
    $ 23.81万
  • 项目类别:
Hypoxic-Inducible Factors in Neonatal Pulmonary Hypertension
新生儿肺动脉高压的缺氧诱发因素
  • 批准号:
    8214146
  • 财政年份:
    2011
  • 资助金额:
    $ 23.81万
  • 项目类别:
Administration
行政
  • 批准号:
    8115244
  • 财政年份:
    2010
  • 资助金额:
    $ 23.81万
  • 项目类别:
HYPOXIA-INDUCIBLE FACTORS IN BPD
BPD 中的缺氧诱导因素
  • 批准号:
    7716092
  • 财政年份:
    2008
  • 资助金额:
    $ 23.81万
  • 项目类别:
CRITICAL TARGETS IN HYPEROXIC MITOCHONDRIAL INJURY
高氧线粒体损伤的关键目标
  • 批准号:
    7716163
  • 财政年份:
    2008
  • 资助金额:
    $ 23.81万
  • 项目类别:
HYPOXIA-INDUCIBLE FACTORS IN BPD
BPD 中的缺氧诱导因素
  • 批准号:
    7562475
  • 财政年份:
    2007
  • 资助金额:
    $ 23.81万
  • 项目类别:
Novel antioxidant therapeutics for sulfur mustard toxicity (U54)
针对硫芥毒性的新型抗氧化疗法 (U54)
  • 批准号:
    7294907
  • 财政年份:
    2006
  • 资助金额:
    $ 23.81万
  • 项目类别:

相似海外基金

Ventilation Model and CNS Injury in Baboons with Bronchopulmonary Dysplasia
支气管肺发育不良狒狒通气模型与中枢神经系统损伤
  • 批准号:
    7246480
  • 财政年份:
    2006
  • 资助金额:
    $ 23.81万
  • 项目类别:
SYNDECANS IN MODELS OF BRONCHOPULMONARY DYSPLASIA
支气管肺发育不良模型中的 SYNDECAN
  • 批准号:
    6390511
  • 财政年份:
    1999
  • 资助金额:
    $ 23.81万
  • 项目类别:
Molecular Targets in Bronchopulmonary Dysplasia
支气管肺发育不良的分子靶点
  • 批准号:
    7118582
  • 财政年份:
    1999
  • 资助金额:
    $ 23.81万
  • 项目类别:
Molecular Targets in Bronchopulmonary Dysplasia
支气管肺发育不良的分子靶点
  • 批准号:
    6803410
  • 财政年份:
    1999
  • 资助金额:
    $ 23.81万
  • 项目类别:
LUNG ELASTIN IN BRONCHOPULMONARY DYSPLASIA
支气管肺发育不良中的肺弹性蛋白
  • 批准号:
    6390507
  • 财政年份:
    1999
  • 资助金额:
    $ 23.81万
  • 项目类别:
Molecular Targets in Bronchopulmonary Dysplasia
支气管肺发育不良的分子靶点
  • 批准号:
    6733432
  • 财政年份:
    1999
  • 资助金额:
    $ 23.81万
  • 项目类别:
SYNDECANS IN MODELS OF BRONCHOPULMONARY DYSPLASIA
支气管肺发育不良模型中的 SYNDECAN
  • 批准号:
    2902045
  • 财政年份:
    1999
  • 资助金额:
    $ 23.81万
  • 项目类别:
LUNG ELASTIN IN BRONCHOPULMONARY DYSPLASIA
支气管肺发育不良中的肺弹性蛋白
  • 批准号:
    6184650
  • 财政年份:
    1999
  • 资助金额:
    $ 23.81万
  • 项目类别:
SYNDECANS IN MODELS OF BRONCHOPULMONARY DYSPLASIA
支气管肺发育不良模型中的 SYNDECAN
  • 批准号:
    6184705
  • 财政年份:
    1999
  • 资助金额:
    $ 23.81万
  • 项目类别:
Molecular Targets in Bronchopulmonary Dysplasia
支气管肺发育不良的分子靶点
  • 批准号:
    6947727
  • 财政年份:
    1999
  • 资助金额:
    $ 23.81万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了